Neurocrine (NBIX) Return on Sales by Net Profit

Graphic logo of Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NBIX) is driving innovation in neuropharmacology through partnerships with global centers. The net operating margin demonstrates effective cost management, where 19.00 indicates the value of this parameter. The business is shielded from external conflicts due to the specific nature of the medical sector. Share prices are supported by Ingrezza sales and the prospects of new molecules for treating depression and schizophrenia.

Neurocrine Corp (NBIX) - Net Margin from 07/04/2022 to 11/20/2026

Analytical breakdowns for Neurocrine Biosciences

- share price and expert price forecast:
Analysis of all company metrics:Neurocrine - NBIX
Manufactured product of Neurocrine Biosciences Inc

For the long-term investor, the resilience of Neurocrine Biosciences (NBIX) is determined by its ability to convert colossal neurobiological research expenditures into net profit. This metric measures the share of final income in revenue, reflecting the efficiency of business scaling following drug registration, which is clearly evidenced by the net profit margin trend, capturing the company's ability to maintain margins amid rising borrowing costs.

Main competitors

BIIB: Net Sales Margin|RGC (Regencell Bioscience Holdings Limited) - Net Margin|Net Margin Axsome Therapeutics Inc|ACAD: Net Profit Rate|Net Sales Margin XENE|Net Sales Margin vikingtherapeutics.com (VKTX)|Net Margin Supernus SUPN|Net Profit Rate CPRX|denalitherapeutics.com - Net Sales Margin|Company Sales Margin Harmony Pharma HRMY|BHVN: Net Sales Margin|Net Margin Amylyx Pharmaceuticals, Inc. (AMLX)|TRVI (Trevi Therapeutics Inc) - Net Sales Margin|Net Return on Sales PRAX (Praxis Medicines)|Net Margin Anavex Life Sciences (AVXL)|Net Margin CBLL (CeriBell EEG)|Net Sales Margin PRTA (Prothena Corp)|alector.com (ALEC) - Net Margin|ANNX: Return on Sales by Net Profit|Net Margin Omeros|NGNE: Net Sales Margin|Return on Sales by Net Profit AC Immune|Return on Sales by Net Profit VYGR|Net Return on Sales NMRA (neumoratx.com)|Return on Sales by Net Profit SCLX (Scilex Holding Company, Inc.)|Net Margin TVGN (Tevogen Bio)|Net Margin Alpha Cognition ACOG|CGTX - Return on Sales by Net Profit|IKT - Net Margin|SAVA: Net Margin|Assertio Therapeutics (ASRT) - Net Margin|Net Margin Coya Therapeutics Inc (COYA)|Net Margin Vistagen|Net Return on Sales OVID (ovidrx.com)|Net Margin Acumen Pharmaceuticals, Inc. (ABOS)|CRVO - Net Margin|Alterity Therapeutics Ltd. - Return on Sales by Net Profit|CLNN - Return on Sales by Net Profit|PEPG - Net Margin|Company Sales Margin jupiterneurosciences.com JUNS|Relmada Therapeutics (RLMD) - Net Margin|ANVS (Annovis Bio, Inc.) - Net Margin|Net Margin gracetx.com|Net Sales Margin Firefly Neuroscience, Inc.|Net Margin ANEW Medical (KLTO)|NRSN - Net Margin|Net Sales Margin RVPH (Reviva Pharmaceuticals Holdings Inc.)|Company Net Profitability MTVA (metaviatx.com)|NeurAxis Inc. - Net Sales Margin|Company Sales Margin heliusmedical.com HSDT|PASG: Net Sales Margin|Neuphoria - Net Profit Rate|Return on Sales by Net Profit NERV|ATHA: Net Profit Rate|Net Margin Addex Therapeutics Ltd (ADXN)|ALZN (Alzamend Neuro Inc.) - Net Profit Rate|Net Sales Margin CYCN (cyclerion.com)|Net Profitability Margin Protagenic|KTTA: Return on Sales by Net Profit|Net Profit Rate CRGT (cortigent.com)|ATXI: Net Sales Margin|BCLI (BrainStorm Cell Therapeutics) - Net Margin|CARA (Cara Therapeutics Inc.) - Net Sales Margin|Net Margin CHRO|Return on Sales by Net Profit ELYM (Eliem Therapeutics)|Net Margin ITCI (Intra-Cellular Therapies Inc.)|Net Sales Margin LBPH (Longboard Pharma)|Net Sales Margin Marinus Pharmaceuticals Inc MRNS|NKGen Biotech Corp - Net Sales Margin|Net Profit Rate NRBO (NeuroBo Pharma)|SAGE (Sage Therapeutics, Inc) - Return on Sales by Net Profit|Net Return on Sales SNPX|Return on Sales by Net Profit TRVN|Net Margin VIGL|Net Sales Margin WENA|Company Sales Margin Cerevel